CytRx Corporation (NASDAQ:CYTR) presented a poster with updated interim results from its on-going Phase 1b/2 trial of aldoxorubicin in combination with ifosfamide/mesna in …
CytRx Corporation (NASDAQ:CYTR) presented results from its on-going Phase 1b/2 trial of aldoxorubicin in combination with ifosfamide/mesna in patients with advanced sarcomas at the …
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months endedJune 30, 2016, and …
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has priced a registered public offering of an …
Jefferies analyst Chris Howerton weighs in on CytRx Corporation (NASDAQ:CYTR) after the company failed to impress investors with its unsuccessful phase 3 Aldoxorubicin (Aldox) trial in …
Shares of CytRx Corporation (NASDAQ:CYTR) are collapsing, down 66% at time of writing, after the company provided initial results from its Phase III study with aldoxorubicin …
Sarepta Therapeutics Inc Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) are on the rise today, after the biotech firm received a request from the FDA to provide additional data …
In a research report released Friday, FBR analyst Christopher James reiterated an Outperform rating on shares of CytRx Corporation (NASDAQ:CYTR), with an $8 price …
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that two members of its clinical development team, Scott Wieland, …
H.C.
